HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience].

AuthorsK Ahmadi-Simab, P Lamprecht, B Hellmisch, W L Gross
JournalZeitschrift fur Rheumatologie (Z Rheumatol) Vol. 63 Issue 6 Pg. 495-7 (Dec 2004) ISSN: 0340-1855 [Print] Germany
Vernacular TitleTherapie der pulmonalen arteriellen Hypertonie (PAH) mit dem oralen Endothelin-Rezeptor Antagonisten Bosentan bei systemischer Sklerose: Die BREATHE-1-Studie und klinische Erfahrungen.
PMID15605216 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antihypertensive Agents
  • Endothelin Receptor Antagonists
  • Sulfonamides
  • Bosentan
Topics
  • Administration, Oral
  • Antihypertensive Agents (therapeutic use)
  • Bosentan
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Endothelin Receptor Antagonists
  • Humans
  • Hypertension, Pulmonary (drug therapy)
  • Physical Endurance (drug effects)
  • Pilot Projects
  • Randomized Controlled Trials as Topic
  • Scleroderma, Systemic (drug therapy)
  • Sulfonamides (therapeutic use)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: